Drug Profile
Research programme: enzyme replacement therapy - Angiochem/Sanofi
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator AngioChem; Genzyme Corporation
- Developer AngioChem; Sanofi
- Class Drug conjugates; Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Lysosomal storage diseases in Canada (Parenteral)
- 28 Feb 2018 No recent reports of development identified for research development in Lysosomal storage diseases in USA (Parenteral)
- 04 Jan 2014 Early research in Lysosomal storage diseases in Canada (Parenteral) prior to January 2014